How to appeal a Highmark radiation oncology — proton, sbrt, brachytherapy, imrt, iort denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for radiation oncology — proton, sbrt, brachytherapy, imrt, iort

Cited policy: Anthem CG-THER-RAD-04 Stereotactic Radiosurgery and SBRT + Anthem clinical guideline Proton Beam Radiation Therapy

IMRT covered when 3D-CRT cannot meet OAR constraints (head and neck, prostate, anal canal, GYN, CNS, selected lung/breast). Dose-escalated IMRT covered in NCCN-supported settings.

How Highmark denies radiation oncology — proton, sbrt, brachytherapy, imrt, iort — and how to counter it

Where Highmark pushes back: 1) IMRT alleged not medically necessary vs 3D-CRT; 2) Re-irradiation experimental; 3) Comparative DVH not on file.

Counter-arguments that hold up: Submit DVH comparison showing 3D-CRT exceeds QUANTEC OAR constraints (e.g., parotid mean dose, heart mean, lung V20, rectum V70, bladder V65). For re-irradiation cite cumulative EQD2 within AAPM TG-101 / Andratschke Radiother Oncol 2022 spine re-RT consensus. Disease-site ASTRO CPG endorses IMRT for H/N, prostate, anal canal, GYN, CNS.

What Highmark typically denies for radiation oncology — proton, sbrt, brachytherapy, imrt, iort

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For radiation oncology — proton, sbrt, brachytherapy, imrt, iort, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the radiation oncology — proton, sbrt, brachytherapy, imrt, iort treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Proton beam therapy
• SBRT prostate
• SBRT lung/liver/spine
• SRS brain
• LDR brachytherapy
• HDR brachytherapy

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.